ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Sunday, October 21, 2018

9:00AM-11:00AM
Abstract Number: 464
The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis
9:00AM-11:00AM
Abstract Number: 254
The Lumbar Spine Is Straight in Fibromyalgia Patients
Fibromyalgia and Other Clinical Pain Syndromes Poster
9:00AM-11:00AM
Abstract Number: 521
The Lung in an English Cohort of Rheumatoid Arthritis Patients – an Overview of Different Types of Involvement and Treatment
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities
9:00AM-11:00AM
Abstract Number: 809
The Lymphangiogenetic Factors VEGF-C, CCL21 and Ang-2 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Systemic Sclerosis and Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 708
The Montreal Cognitive Assessment Test. a Useful Tool in Screening of Cognitive Impairment in Patients with Systemic Lupus Erythematosusshort Title: Cognitive Impairment in SLE
Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity
9:00AM-11:00AM
Abstract Number: 327
The Patient Global Assessment and Common Composite Disease Activity Measures Vary Minimally When Patients Reflect on Their Arthritis or Their Global Health: Results from the Canadian Early Arthritis Cohort Study
Measures and Measurement of Healthcare Quality Poster I
9:00AM-11:00AM
Abstract Number: 36
The Pleiotropic Effects of TAM Signaling on Inflammatory Arthritis in Mice Using Kbxn Serum Transfer Induced Arthritis
Rheumatoid Arthritis – Animal Models Poster
9:00AM-11:00AM
Abstract Number: 429
The Potential Clinical Relevance of Imaging Biomarker Data from Short-Term Interventional Trials in Osteoarthritis: A Comparison of the Cathepsin K Inhibitor Miv-711 Phase 2a MRI Knee Joint Data and KL-Matched 5577 Knee Control Data from the Osteoarthritis Initiative
Osteoarthritis – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 441
The Presence of Neuropathic Pain Does Not Influence the Response to Hyaluronic Acid (HA) in Patients with Knee Osteoarthritis but HA Injections Modify Pain Phenotype
Osteoarthritis – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 523
The Prevalence and Clinical Characteristics of Rheumatoid Arthritis with Interstitial Lung Disease in the San Joaquin Valley of Central California
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities
9:00AM-11:00AM
Abstract Number: 467
The Prevalence and Clinical Features of Co-Occurring Autoimmunity in Children with Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry
Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis
9:00AM-11:00AM
Abstract Number: 286
The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases
Health Services Research Poster I – ACR/ARHP
9:00AM-11:00AM
Abstract Number: 789
The Relationship between YKL-40 and Vascular Endothelial Growth Factor in Angiogenesis in Systemic Sclerosis Patients
Systemic Sclerosis and Related Disorders – Clinical Poster I
9:00AM-11:00AM
Abstract Number: 28
The Rho Kinase Family Member, ROCK2, Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity
B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 83
The Risk of Developing Rheumatoid Arthritis Based on HLA-DQ Genotypes
Rheumatoid Arthritis – Etiology and Pathogenesis Poster I
  • «Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 67
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology